Cancer immunotherapy beyond immune checkpoint inhibitors

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design

(2018) Pamela A. Trail et al.   PHARMACOLOGY & THERAPEUTICS

INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT-301, A NOVEL PYRROLOBENZODIAZAPINE-BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON-HODGKIN LYMPHOMA

(2017) S.M. Horwitz et al.   HEMATOLOGICAL ONCOLOGY

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

(2017) Khaldoun Almhanna et al.   INVESTIGATIONAL NEW DRUGS

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors

(2017) Andres Forero et al.   INVESTIGATIONAL NEW DRUGS

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

(2017) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

(2017) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Reply to Á. Benedict et al

(2017) Christine G. Kohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive Reporting in Cost-Effectiveness Modeling

(2017) Ágnes Benedict et al.   JOURNAL OF CLINICAL ONCOLOGY

To The Last Drop

(2017) Daniel Rayson   JOURNAL OF CLINICAL ONCOLOGY

Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?

(2017) Amy Jo Chien et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

(2017) Efrat Dotan et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary care physicians experiences of caring for cancer survivors: Toward developing a primary care-responsive cancer survivorship research agenda.

(2017) Denalee M. O'Malley et al.   JOURNAL OF CLINICAL ONCOLOGY

Sickness Absence and Disability Pension After Breast Cancer Diagnosis: A 5-Year Nationwide Cohort Study

(2017) Pia Kvillemo et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

(2017) Frank (Xiaohu) Fan et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical trials of CAR-T cells in China

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

(2017) Erhao Zhang et al.   Journal of Hematology & Oncology

Chimeric antigen receptor T cells: a novel therapy for solid tumors

(2017) Shengnan Yu et al.   Journal of Hematology & Oncology

MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial

(2017) Daniel Morgensztern et al.   Journal of Thoracic Oncology

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer

(2017) April A.N. Rose et al.   PHARMACOLOGY & THERAPEUTICS

Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer

(2017) Kecheng Zhang et al.   Journal of Cancer

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

(2017) et al.   Cancers

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

(2016) J. M. Pitt et al.   ANNALS OF ONCOLOGY

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

(2016) A. Viardot et al.   BLOOD

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Abstract CT032: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma

(2016) Robert A. Jabulowsky et al.   CANCER RESEARCH

Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer

(2016) A Forero et al.   CANCER RESEARCH

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

(2016) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

ERRATUM

(2016)   JOURNAL OF CLINICAL ONCOLOGY

Valproate in Adjuvant Glioblastoma Treatment

(2016) Michael F. Fay et al.   JOURNAL OF CLINICAL ONCOLOGY

The characteristics of pancreatic neck cancer.

(2016) Hiroki Yamaue et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinicopathological features of ruptured GIST in the ReGISTry study of high risk GIST patients after complete resection in Japan.

(2016) Toshirou Nishida et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.

(2016) Nathan Bahary et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging therapeutic agents for lung cancer

(2016) Bhagirathbhai Dholaria et al.   Journal of Hematology & Oncology

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

The oncolytic peptide LTX-315 triggers immunogenic cell death

(2016) H Zhou et al.   Cell Death & Disease

Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment

(2016) Manuela Liguori et al.   Oncotarget

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

(2016) Hasan Rehman et al.   Journal for ImmunoTherapy of Cancer

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6

(2015) L. M. Draper et al.   CLINICAL CANCER RESEARCH

3336 Phase II CALM extension study: Enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21

(2015) R.H.I. Andtbacka et al.   EUROPEAN JOURNAL OF CANCER

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

(2015) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

(2015) Jingjing Wu et al.   Journal of Hematology & Oncology

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

(2015) Jingjing Wu et al.   Journal of Hematology & Oncology

Bispecific antibodies and their applications

(2015) Gaowei Fan et al.   Journal of Hematology & Oncology

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

IMPS-03INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OF GLIOMA

(2015) John A. Barrett et al.   NEURO-ONCOLOGY

Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs

(2015) Rachid Ammi et al.   PHARMACOLOGY & THERAPEUTICS

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

(2015) Kimberly A. Noonan et al.   Science Translational Medicine

IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?

(2015) Jakub Tomala et al.   OncoImmunology

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

(2015) Yong Wha Moon et al.   Journal for ImmunoTherapy of Cancer

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Interleukin 12: still a promising candidate for tumor immunotherapy?

(2014) Witold Lasek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment

(2014) Ulrich H. Weidle et al.   SEMINARS IN ONCOLOGY

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma

(2014) Alessandra Soriani et al.   OncoImmunology

Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer

(2013) May C.I. van Schalkwyk et al.   Human Gene Therapy Clinical Development

DARTs take aim at BiTEs

(2011) C. Rader   BLOOD

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing

(2010) Coen Govers et al.   TRENDS IN MOLECULAR MEDICINE

WT1 peptide vaccine for the treatment of cancer

(2008) Yoshihiro Oka et al.   CURRENT OPINION IN IMMUNOLOGY